Psilera Inc. is a biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic-derived therapies focused on novel treatments for neuropsychiatric disorders.
The company is developing PSIL-006, a first-in-class neuroplastogen designed to provide therapeutic benefits of traditional psychedelic compounds while minimizing hallucinogenic effects and cardiovascular risks, with plans to advance the asset into first-in-human trials.
Leadership & Board
Currently, no data available
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$9M
Total Amount Raised$9M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$9M
Latest Funding Amount$9M
Latest Funding RoundSeed Round
Latest Funding RoundSeed Round
Post-Money Valuation―
Post-Money Valuation―
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
May 28, 2026
Seed Round
$8.80M
―
Similar Companies
A snapshot of private companies similar to Psilera Inc, helping you discover and navigate related company profiles.